<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ligand Pharms Glucagon — News on 6ix</title>
    <link>https://6ix.com/company/ligand-pharms-glucagon</link>
    <description>Latest news and press releases for Ligand Pharms Glucagon on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/ligand-pharms-glucagon" rel="self" type="application/rss+xml" />
    <item>
      <title>Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligands-position-as-a-leading-biopharma-royalty-aggregator-2</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligands-position-as-a-leading-biopharma-royalty-aggregator-2</guid>
      <pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
      <description>Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50</description>
    </item>
    <item>
      <title>Ligand to Report First Quarter 2026 Financial Results on May 7, 2026</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-report-first-quarter-2026-financial-results-on-may-7-2026-2</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-report-first-quarter-2026-financial-results-on-may-7-2026-2</guid>
      <pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
      <description>JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, May 7, 2026 Time: 8:30 a.m. Eastern time Conference Call: United States (Local): +1 (585) 542-9983 United</description>
    </item>
    <item>
      <title>Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-partner-travere-therapeutics-receives-full-fda-approval-for-filsparir-sparsentan-in-fsgs-2</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-partner-travere-therapeutics-receives-full-fda-approval-for-filsparir-sparsentan-in-fsgs-2</guid>
      <pubDate>Tue, 14 Apr 2026 11:00:00 GMT</pubDate>
      <description>FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to reduce proteinuria in adult and pediat</description>
    </item>
    <item>
      <title>Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-advances-strategic-growth-with-expanded-and-strengthened-business-development-team-2</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-advances-strategic-growth-with-expanded-and-strengthened-business-development-team-2</guid>
      <pubDate>Thu, 26 Mar 2026 11:00:00 GMT</pubDate>
      <description>JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development. Both will report to Paul Hadden, Ligand’s Senior Vice President of Investments and Business Development. Dr. Renehan comes to the firm from Blackstone Life Sciences, where he served as a Principal. He was previously in healthcare investmen</description>
    </item>
    <item>
      <title>Ligand Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-reports-fourth-quarter-and-full-year-2025-financial-results-2</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-reports-fourth-quarter-and-full-year-2025-financial-results-2</guid>
      <pubDate>Thu, 26 Feb 2026 12:00:00 GMT</pubDate>
      <description>Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share1 of $8.00-$9.00 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2025, and provided an operating forecast and bu</description>
    </item>
    <item>
      <title>Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026-1</guid>
      <pubDate>Thu, 12 Feb 2026 12:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, February 26, 2026 Time: 8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. &amp; Canada)(646)</description>
    </item>
    <item>
      <title>Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-1</guid>
      <pubDate>Wed, 04 Feb 2026 12:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which will be held virtually, on February 25, 2026 at 10:00 a.m. Eastern Time. Ligand management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investor</description>
    </item>
    <item>
      <title>Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-reports-third-quarter-2025-financial-results-and-raises-guidance-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-reports-third-quarter-2025-financial-results-and-raises-guidance-1</guid>
      <pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
      <description>Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnings per diluted share1 increased to $7.40 - $7.65 (previously $6.70 - $7.00) Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and ni</description>
    </item>
    <item>
      <title>Ligand to Participate in November Investor Conferences</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-participate-in-november-investor-conferences-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-participate-in-november-investor-conferences-1</guid>
      <pubDate>Thu, 30 Oct 2025 20:01:00 GMT</pubDate>
      <description>JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: UBS Global Healthcare Conference (Palm Beach Gardens): Management will participate in one-on-one meetings on November 10, 2025.Stifel 2025 Healthcare Conference (New York): Management will participate in a fireside chat on November 12, 2</description>
    </item>
    <item>
      <title>Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-report-third-quarter-2025-financial-results-on-november-6-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-report-third-quarter-2025-financial-results-on-november-6-2025-1</guid>
      <pubDate>Thu, 23 Oct 2025 11:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date:Thursday, November 6, 2025 Time:8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. &amp; Canada)(646) 307-1963 (Internat</description>
    </item>
    <item>
      <title>Ligand to Host Investor Day on December 9, 2025</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-host-investor-day-on-december-9-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-host-investor-day-on-december-9-2025-1</guid>
      <pubDate>Thu, 16 Oct 2025 11:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9, 2025 from 10:30 a.m. to 12:00 p.m. Eastern Time at The Harvard Club. The event will include presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza and other members of the Ligand senior management team. Presentations will highlight the company’s strategy, investment activity, royalty portfoli</description>
    </item>
    <item>
      <title>Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-partner-sq-innovation-receives-fda-approval-for-lasixr-onyu-an-at-home-treatment-for-edema-in-heart-failure-patients-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-partner-sq-innovation-receives-fda-approval-for-lasixr-onyu-an-at-home-treatment-for-edema-in-heart-failure-patients-1</guid>
      <pubDate>Thu, 09 Oct 2025 11:00:00 GMT</pubDate>
      <description>Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled™ approved product JUPITER, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner SQ Innovation Inc. has received approval from the U.S. Food and Drug Administration (FDA) for Lasix® ONYU (furosemide injection), a novel drug-device combination for the treatment o</description>
    </item>
    <item>
      <title>Ligand to Participate in September Investor Conferences</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-participate-in-september-investor-conferences-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-participate-in-september-investor-conferences-1</guid>
      <pubDate>Tue, 19 Aug 2025 20:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on Septemb</description>
    </item>
    <item>
      <title>Ligand Announces Closing of Convertible Senior Notes Offering</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-announces-closing-of-convertible-senior-notes-offering-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-announces-closing-of-convertible-senior-notes-offering-1</guid>
      <pubDate>Thu, 14 Aug 2025 20:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.75% convertible senior notes due 2030 (the “notes”). The aggregate principal amount of the notes sold in the offering was $460.0 million, which includes the purchase of an additional $60.0 million aggregate principal amount of notes by the initial purchasers pursuant to the full exercise of the ini</description>
    </item>
    <item>
      <title>Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-announces-pricing-of-dollar400-million-convertible-senior-notes-offering-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-announces-pricing-of-dollar400-million-convertible-senior-notes-offering-1</guid>
      <pubDate>Tue, 12 Aug 2025 03:46:00 GMT</pubDate>
      <description>JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ligand also granted the initial purchasers of the notes (the</description>
    </item>
    <item>
      <title>Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-announces-proposed-offering-of-dollar400-million-of-convertible-senior-notes-due-2030-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-announces-proposed-offering-of-dollar400-million-of-convertible-senior-notes-due-2030-1</guid>
      <pubDate>Mon, 11 Aug 2025 11:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors. Ligand als</description>
    </item>
    <item>
      <title>Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-reports-second-quarter-2025-financial-results-and-raises-guidance-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-reports-second-quarter-2025-financial-results-and-raises-guidance-1</guid>
      <pubDate>Thu, 07 Aug 2025 11:00:00 GMT</pubDate>
      <description>Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earnings per diluted share1 increased to $6.70 - $7.00 (previously $6.00 - $6.25) Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and s</description>
    </item>
    <item>
      <title>Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-and-medtronic-commit-dollar70-million-in-strategic-capital-to-orchestra-biomed-3</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-and-medtronic-commit-dollar70-million-in-strategic-capital-to-orchestra-biomed-3</guid>
      <pubDate>Thu, 31 Jul 2025 20:01:00 GMT</pubDate>
      <description>• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in an equity private placement and an additional $20 million in a secured subordinated promissory note convertible to prepaid revenue share • Medtronic and Orchestra BioMed expand strategic collaboration to provide pathway for development of AVIM therapy-enabled leadless pacemakers</description>
    </item>
    <item>
      <title>Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-report-second-quarter-2025-financial-results-on-august-7-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/ligand-to-report-second-quarter-2025-financial-results-on-august-7-2025-1</guid>
      <pubDate>Thu, 24 Jul 2025 11:00:00 GMT</pubDate>
      <description>JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, August 7, 2025 Time: 8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. &amp; Canada)(646) 307-1963 (Internati</description>
    </item>
    <item>
      <title>LGND Raises $9M to Make Earth Data Intuitive and Actionable</title>
      <link>https://6ix.com/company/ligand-pharms-glucagon/news/lgnd-raises-dollar9m-to-make-earth-data-intuitive-and-actionable-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharms-glucagon/news/lgnd-raises-dollar9m-to-make-earth-data-intuitive-and-actionable-1</guid>
      <pubDate>Thu, 10 Jul 2025 14:43:00 GMT</pubDate>
      <description>LGND AI, Inc., a company building new ways for people and AI to interact with Earth data, today announced it has raised $9 million in financing. The round was led by Javelin Venture Partners, with participation from AENU, Space Capital, Overture, Ridgeline, MCJ, Coalition Operators, Clocktower Ventures, and more. Notable angel investors include John Hanke, founder of Keyhole (acquired by Google and the foundation for Google Maps and Niantic), Karim Atiyeh, cofounder and CTO of Ramp, and Suzanne</description>
    </item>
  </channel>
</rss>